Zorevunersen shows long-lasting seizure control in Dravet patients
Zorevunersen continues to show durable reductions in seizure frequency — alongside gains in cognition, behavior, and day-to-day functioning — in children and adolescents followed for up to three years. The investigational therapy targets the genetic cause of Dravet syndrome. The findings come from two long-term extension studies that followed…